Curcumin and Anti-PD Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments involving antibodies targeting PD-1, PD-L1, or PD-L2 often fail to achieve desired therapeutic effects in some cases, necessitating a novel approach to enhance anti-tumor activity.
Innovation Solution
Combining antibodies against PD-1, PD-L1, or PD-L2 with curcumin or its derivatives to synergistically enhance anti-tumor effects and suppress cancer cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies are used for cancer treatment, then T-cell activation is enhanced and immune function is recovered, but in some cases sufficient therapeutic effects are not achieved
Solution Approach 1:
The patent combines curcumin (a natural compound with anti-proliferative properties) with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies to create a composite therapeutic agent. This merging of substances with different mechanisms of action addresses cases where single-antibody therapy is insufficient, thereby improving reliability and adaptability of cancer treatment.
Solution Approach 2:
The invention creates a composite therapeutic formulation consisting of curcumin and checkpoint inhibitor antibodies. This composite approach leverages the immunomodulatory effects of the antibodies combined with the direct anti-proliferative and pro-apoptotic effects of curcumin on cancer cells, providing enhanced and more versatile therapeutic outcomes.
2Reliability
If curcumin and anti-PD-1/PD-L1/PD-L2 antibodies are used in combination, then anti-tumor effect is synergistically enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges curcumin and checkpoint inhibitor antibodies into a single combination therapy regimen. By integrating these two therapeutic agents with complementary mechanisms into one treatment protocol, the patent achieves synergistic anti-tumor effects while managing complexity through coordinated administration rather than separate, uncoordinated therapies.
Data Source
AI summary
To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.